Amylyx’s amyotrophic lateral sclerosis (ALS) drug, marketed as Relyvrio, has been approved by the FDA for the treatment of ALS in adults at a cost of $158,000 per year. The first FDA advisory meeting ended with a 6-4 vote. However, the company remained persistent and the committee’s considerations resulted in a 7-2 decision in September. The drug developing company had no idea when or if its drug would receive approval. The lengthy period of time allowed it to persistently prepare for a potential launch.
Read More from FiercePharma
English